Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
- DOI
- 10.1080/21678707.2021.1882300
- Published
- 2021
- Container
- Expert opinion on orphan drugs
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/21678707.2021.1882300,
title = {Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?},
author = {Han RC and Fry LE and Kantor A and McClements ME and Xue K and MacLaren RE},
year = {2021},
journal = {Expert opinion on orphan drugs},
doi = {10.1080/21678707.2021.1882300},
url = {https://doi.org/10.1080/21678707.2021.1882300}
}RIS
TY - JOUR TI - Is subretinal AAV gene replacement still the only viable treatment option for choroideremia? AU - Han RC AU - Fry LE AU - Kantor A AU - McClements ME AU - Xue K AU - MacLaren RE PY - 2021 JO - Expert opinion on orphan drugs DO - 10.1080/21678707.2021.1882300 UR - https://doi.org/10.1080/21678707.2021.1882300 ER -
APA
RC, H., LE, F., A, K., ME, M., K, X., & RE, M. (2021). Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?. Expert opinion on orphan drugs. https://doi.org/10.1080/21678707.2021.1882300
Source records
- pubmed · retrieved 2026-09-26T18:54:19.292Z